# Asthma management in France and the United Kingdom

First published: 27/10/2015

Last updated: 01/04/2024





## Administrative details

EU PAS number
EUPAS11410
Study ID
26340
DARWIN EU® study
No
Study countries
France
United Kingdom

### **Study description**

This study will compare asthma management between patients in the United Kingdom and in France, in particular with regards to "at-risk" treatment patters.

Two successive cohorts of persistent patients will be defined in 2007/2008 and in 2013/2014. Comparisons of asthma management between 2007 and 2013 will be made within countries to determine if there are any changes in "at-risk" management. Between countries, comparisons will be made to determine if there are differences in managements. For the latter analysis, only the 2013/2014 cohort will be used.

#### **Study status**

**Finalised** 

### Research institutions and networks

### Institutions



# Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

First published: 06/10/2015
Last updated: 19/08/2024
Institution Educational Institution Laboratory/Research/Testing facility
ENCePP partner

# Networks

Respiratory Effectiveness Group (REG)
☐ Belgium
☐ Denmark
France
Germany
Greece
Hungary
Italy
☐ Netherlands
Spain
Sweden
United Kingdom
First published: 07/07/2021
Last updated: 04/06/2024
Network ENCePP partner

# Contact details

#### **Study institution contact**

## David Van Ganse sanne@effectivenessevaluation.org

Study contact

sanne@effectiveness evaluation.org

#### **Primary lead investigator**

David Van Ganse

**Primary lead investigator** 

# Study timelines

### Date when funding contract was signed

Planned: 30/10/2015

Actual: 01/10/2015

#### Study start date

Planned: 30/10/2015

Actual: 07/10/2015

### Data analysis start date

Planned: 02/11/2015

Actual: 02/11/2015

#### **Date of final study report**

Planned: 29/01/2016

Actual: 13/10/2016

### Sources of funding

Other

## More details on funding

Claude-Bernard-Lyon1 University

### Study protocol

Asthma management between France and the United Kingdom\_V7 (1).pdf (621.28 KB)

# Regulatory

Was the study required by a regulatory body?

Unknown

Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

Study type

Study type list

**Study topic:** 

Disease /health condition

#### Study type:

Non-interventional study

#### Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness Other

#### If 'other', further details on the scope of the study

Asthma management comparison

#### **Data collection methods:**

Secondary use of data

#### Main study objective:

To compare asthma management between patients in the United Kingdom and in France, in particular with regards to at-risk treatment patterns.

### Study Design

#### Non-interventional study design

Other

### Non-interventional study design, other

Historical observational, cohort study

# Study drug and medical condition

#### Medical condition to be studied

**Asthma** 

# Population studied

#### Short description of the study population

French patients: aged 6 to 40 years with at least 3 dispensations of respiratory drug (R03 ATC code except R03DX05, R03AC18, R03BB04, R03BB01, R03AK03 and R03AK04) in 2007/2013 at 3 different dates will qualify to enter the cohort. The date of entry in the cohort will be the date of the 3rd dispensation (entry date).

UK patients: aged 6 to 40 years with a diagnosis of asthma recorded in the database in 2007/2013. Patients older than 40 will be described as well in a complementary analysis, but they will not be compared to French patients.

#### **Age groups**

Adolescents (12 to < 18 years)
Adults (18 to < 46 years)

#### **Special population of interest**

Other

#### Special population of interest, other

Asthma patients

#### **Estimated number of subjects**

35000

# Study design details

#### **Outcomes**

Describe asthma managements with regards to the following:1. LABA with no ICS prescription (Monotherapy)2. Ratio units dispensed of LABA/ICS >= 2 (unit=canisters or prescriptions in the UK)3. High use of SABAs (>= 12 canisters

#### Data analysis plan

Asthma managements will be described with regards to the following:1. LABA with no ICS prescription (Monotherapy)2. Ratio units dispensed of LABA/ICS >= 2 (unit= canisters or prescriptions in the UK)3. High use of SABAs (>= 12 canisters dispensed/prescribed)Comparisons will be made:1. Within country: This will compare asthma management in 2007/2008 vs 2013/20142. Between countries: Differences in management between countriesTreatment groups will be compared using t-test / Mann Whitney U-test (depending on distribution) for variables measured on the interval/ratio scale and using a chi square test for categorical variables.

### **Documents**

#### Study publications

Belhassen M, Nibber A, Van Ganse E, Ryan D, Langlois C, Appiagyei F, Skinner D,...

## Data management

### Data sources

#### Data source(s)

Optimum Patient Care Research Database

#### Data source(s), other

EGB database (1/97th random sample of the national French claims data)

#### Data sources (types)

Electronic healthcare records (EHR)

## Use of a Common Data Model (CDM)

#### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

### **Check completeness**

Unknown

#### **Check stability**

Unknown

### **Check logical consistency**

Unknown

### Data characterisation

#### **Data characterisation conducted**

Unknown